ES2013394A6 - Procedimiento para preparar una composicion farmaceutica de relaxina humana biologicamente activa. - Google Patents

Procedimiento para preparar una composicion farmaceutica de relaxina humana biologicamente activa.

Info

Publication number
ES2013394A6
ES2013394A6 ES8900688A ES8900688A ES2013394A6 ES 2013394 A6 ES2013394 A6 ES 2013394A6 ES 8900688 A ES8900688 A ES 8900688A ES 8900688 A ES8900688 A ES 8900688A ES 2013394 A6 ES2013394 A6 ES 2013394A6
Authority
ES
Spain
Prior art keywords
biologically active
active human
human relaxin
procedure
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8900688A
Other languages
English (en)
Inventor
David C Cipolla
Tue H Nguyen
Steven J Shire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Genetech Inc
Original Assignee
Genentech Inc
Genetech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Genetech Inc filed Critical Genentech Inc
Publication of ES2013394A6 publication Critical patent/ES2013394A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA DE RELAXINA HUMANA BIOLOGICAMENTE ACTIVA. PROCEDIMIENTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA DE RELAXINA HUMANA BIOLOGICAMENTE ACTIVA. CONSISTE EN INCORPORAR A UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE UNA CANTIDAD DE RELAXINA HUMANA BIOLOGICAMENTE ACTIVA DE APROXIMADAMENTE 0,01% A 2% EN PESO, AÑADIR UN TAMPON CAPAZ DE MANTENER EL PH DE LA COMPOSICION EN UN VALOR DESDE APROXIMADAMENTE 4 HASTA MENOS DE APROXIMADAMENTE 7, SIENDO LA CANTIDAD DE DICHO TAMPON DE APROXIMADAMENTE 0,001% A 0,5% EN PESO, AGREGAR OPCIONALMENTE UN AGENTE DE AJUSTE DE LA ISOTONICIDAD Y LA OSMOLALIDAD, UN AGENTE ESTABILIZADOR Y UN AGENTE MEJORADOR DE LA ABSORCION, ASI COMO OTROS INGREDIENTES EVENTUALMENTE NECESARIOS, Y DAR A LA COMPOSICION RESULTANTE UNA FORMA DE ADMINISTRACION APROPIADA LIQUIDA, LIOFILIZADA, CONGELADA O GELIFICADA. EL INVENTO ES UTIL PARA MODULAR LA FISIOLOGIA REPRODUCTIVA EN HUMANOS Y OTROS MAMIFEROS, MEJORANDO EL PARTO Y EVITANDO QUE SEAPREMATURO.
ES8900688A 1988-02-26 1989-02-24 Procedimiento para preparar una composicion farmaceutica de relaxina humana biologicamente activa. Expired - Lifetime ES2013394A6 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16079788A 1988-02-26 1988-02-26
US30377989A 1989-01-27 1989-01-27

Publications (1)

Publication Number Publication Date
ES2013394A6 true ES2013394A6 (es) 1990-05-01

Family

ID=26857232

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8900688A Expired - Lifetime ES2013394A6 (es) 1988-02-26 1989-02-24 Procedimiento para preparar una composicion farmaceutica de relaxina humana biologicamente activa.

Country Status (14)

Country Link
US (2) US5451572A (es)
EP (1) EP0407401B1 (es)
JP (1) JP2815649B2 (es)
CN (1) CN1052655C (es)
AT (1) ATE88352T1 (es)
AU (1) AU626840B2 (es)
CA (1) CA1336403C (es)
DE (1) DE68906153T2 (es)
ES (1) ES2013394A6 (es)
IE (1) IE63208B1 (es)
IL (1) IL89276A (es)
NZ (1) NZ228012A (es)
PT (1) PT89835B (es)
WO (1) WO1989007945A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
AU3123393A (en) * 1991-10-28 1993-06-07 Board Of Regents, The University Of Texas System A method for detecting a differentiation marker in normal and carcinoma cells and in biological samples and body fluid
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5830848A (en) * 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
EP0782850A4 (en) * 1994-10-13 1998-03-04 Wakamoto Pharma Co Ltd LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
ES2187667T3 (es) 1995-08-15 2003-06-16 Connetics Corp Uso de relaxina para estimular angiogenesis.
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US5994148A (en) * 1997-06-23 1999-11-30 The Regents Of University Of California Method of predicting and enhancing success of IVF/ET pregnancy
US6251863B1 (en) 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin
EP1140001B1 (en) * 1998-12-18 2005-05-04 Palladin HealthCare International Ltd Composition for treatment of burns
ATE362770T1 (de) * 2000-02-09 2007-06-15 Bas Medical Inc Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
US20050032683A1 (en) 2000-10-04 2005-02-10 Amento Edward P. Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
US7660678B2 (en) * 2004-02-05 2010-02-09 Medpro Holdings, Llc On-site method of providing analysis of potency and purity of pharmaceutical compounds
US20100134794A1 (en) * 2004-02-05 2010-06-03 Medpro Holdings, Llc Analyzer for determining the concentration, potency and purity of pharmaceutical compounds
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2005115435A2 (en) * 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US20060052304A1 (en) * 2004-09-02 2006-03-09 Bas Medical, Inc. Method for remodeling bone and related sutures
US20080241260A1 (en) * 2005-09-28 2008-10-02 Padma Venkitachalam Devarajan Compositions for Enhanced Absorption of Biologically Active Agents
CN102026650A (zh) * 2008-05-16 2011-04-20 科尔泰拉公司 预防早产的方法
AU2009246333B2 (en) * 2008-05-16 2013-05-09 Corthera, Inc. Method of promoting wound healing
WO2010105081A1 (en) 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
KR101800040B1 (ko) 2010-03-10 2017-11-21 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 릴랙신을 사용한 아쿠아포린의 조절
PE20140160A1 (es) 2010-08-17 2014-02-08 Ambrx Inc Polipeptidos de relaxina modificados y sus usos
CN102133200B (zh) * 2011-03-16 2012-07-25 济南环肽医药科技有限公司 一种人类松弛素-2 Relaxin的注射用冻干粉制剂
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
CN103768584A (zh) * 2014-02-10 2014-05-07 济南环肽医药科技有限公司 一种松弛肽注射液
CN104922661B (zh) * 2014-03-20 2018-08-24 深圳翰宇药业股份有限公司 一种含有serelaxin的药物组合物及其制备方法
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
CN107007822A (zh) * 2016-01-27 2017-08-04 江苏恒瑞医药股份有限公司 一种含有重组人松弛素‑2类似物的药物组合物及其制备方法
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
EP4791358A1 (en) * 2023-09-15 2026-08-19 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Relaxin medication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2964448A (en) * 1959-01-27 1960-12-13 Anschel Joachim Relaxin composition and process for preparing same
US3003117A (en) * 1959-09-29 1961-10-03 Gen Frecision Inc Coincident frequency tracker
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4267101A (en) * 1980-02-01 1981-05-12 Serono Laboratories Inc. Process for obtaining human relaxin from fetal membranes
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
EP0101309B1 (en) * 1982-08-12 1991-01-16 Howard Florey Institute Of Experimental Physiology And Medicine Molecular cloning and characterization of a gene sequence coding for human relaxin
DE3236264A1 (de) 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur gewinnung von relaxin
DE3236267A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur herstellung von relaxin und verfahren zur hochreinigung von relaxin
IL70414A (en) * 1982-12-13 1991-06-10 Florey Howard Inst Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
EP0260149A1 (en) * 1986-09-12 1988-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Human prorelaxin for therapeutic use
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor

Also Published As

Publication number Publication date
CN1035619A (zh) 1989-09-20
AU626840B2 (en) 1992-08-13
PT89835B (pt) 1994-01-31
US5451572A (en) 1995-09-19
ATE88352T1 (de) 1993-05-15
WO1989007945A1 (en) 1989-09-08
JP2815649B2 (ja) 1998-10-27
DE68906153T2 (de) 1993-10-28
EP0407401B1 (en) 1993-04-21
JPH03502794A (ja) 1991-06-27
IE63208B1 (en) 1995-04-05
US5945402A (en) 1999-08-31
EP0407401A1 (en) 1991-01-16
CA1336403C (en) 1995-07-25
IL89276A0 (en) 1989-09-10
IL89276A (en) 1994-06-24
IE890452L (en) 1989-08-26
CN1052655C (zh) 2000-05-24
PT89835A (pt) 1989-10-04
DE68906153D1 (de) 1993-05-27
NZ228012A (en) 1991-07-26
AU3183389A (en) 1989-09-22

Similar Documents

Publication Publication Date Title
DE69435033T2 (de) Parathormonarzneizusammensetzung
DE69102465T2 (de) Stabilisierte Gonadotropin enthaltende Zubereitungen.
DE68924491T2 (de) Intrascheidenabgabe von aktiven Polypeptiden.
DE69233704T2 (de) Stabilisierte pharmazeutische Formulierung, umfassend Wachstumshormon und Histidin
EP1417972B2 (en) Stabilized teriparatide solutions
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
KR890003400A (ko) 경비(經鼻)투여용 생리 활성 펩티드 분말 조성물(제제)
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
IL89276A0 (en) Human relaxin formulation
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
Taylor et al. Testosterone in a cyclodextrin-containing formulation: behavioral and physiological effects of episode-like pulses in rats
KR900015749A (ko) 인터루킨-1제형
AR017973A1 (es) Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo
DE69229318D1 (de) Hydrierte Rizinusöl-enthaltende injizierbare Formulierungen mit verlängerter Wirkstoffabgabe
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
ATE424192T1 (de) Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten
EP1097712A4 (en) STAPS CONTAINING CATAPLASMS AND METHOD OF MANUFACTURING SAME
MX9307991A (es) Analogos de insulina, procedimiento para su preparacion y formulaciones farmaceuticas que los incluyen.
IL87778A (en) Topical pharmaceutical compositions in the form of a hydrogel containing stabilized therapeutically active proteins and their preparation
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ES2146231T3 (es) Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas.
EP0914827A4 (en) OPHTHALMIC DRUG COMPOSITIONS
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20110301